A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

Recruiting

Phase 2

HU6A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

Sponsor:

Rivus Pharmaceuticals, Inc.

Code:

NCT07491458

Conditions

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Eligibility Criteria

Sex: All

Age: 30+

Healthy Volunteers: Not accepted

Interventions

HU6

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-22. This information was provided to ClinicalTrials.gov by Rivus Pharmaceuticals, Inc. on 2026-05-18.